Pioneering preventive treatments for rare bleeding disorders.
Hemab aims to revolutionize the standard of care for patients worldwide. As an innovative biopharmaceutical company in its clinical phase, they are developing the first prophylactic treatments for severe bleeding disorders. The company has rapidly grown in both staff and size, securing over 1 billion in funding.
”A bleeding or thrombotic event can occur at any time, from a simple menstruation to a routine dental procedure, potentially leading to severe symptoms. By the time one reaches a hospital, it may be too late. It is time to ensure that every patient with a coagulation disorder has the safety and peace of mind they deserve.”